싸이토젠

217330KOSDAQ

53.3 / 100

Reference Date: 2026-09-08

Financial Score17.0 / 40

News Sentiment21.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 10.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CytoGen focuses on liquid biopsy platforms based on CTC (Circulating Tumor Cells) technology, offering services such as supporting anti-cancer drug development, precision medicine, and health supplement sales. Key business areas include companion diagnostics development with pharmaceutical companies, medical device distribution, and health supplement sales, while also expanding globally through research and international collaborations.

Number of Employees

39people

Average Salary

64.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.96Industry Average 1.201.0Point

1.6x industry avg (risky)

ROE

-29.06Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

31.95Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲190.7% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲16.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -38.7% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
싸이토젠, 역대 최대 반기 매출 경신…영업손실 37% 축소
싸이토젠의 반기 매출이 역대 최대치를 기록하며, 핵심 자회사 인수와 CTC 사업 강화로 인한 긍정적인 성장이 확인되었다.

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 3,055Won52-week high 9,42052-week low 2,320

1-month return1.0Point

1m -10.93% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-09-02
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-02
Neutral주식등의대량보유상황보고서(일반)2026-09-02
Neutral기타경영사항(자율공시) (소규모합병 승인 이사회 결의(주주총회 갈음) 결과 보고)2026-08-31
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-08-27